<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00778492</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-08-5119-SP-CTIL</org_study_id>
    <nct_id>NCT00778492</nct_id>
  </id_info>
  <brief_title>Thrombelastogram in Patients Receiving Antiplatelet Medication Undergoing Cardiac Surgery</brief_title>
  <official_title>Thrombelastogram and Predicting Microvascular Bleeding in Patients Receiving Antiplatelet Medication Undergoing Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Objective is to correlate the results of preoperative platelet mapping derived from
      modified TEG with clinically significant postoperative bleeding and consumption of blood
      products.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design:

      Prospective observational study with blinded assessment of study endpoint variables.
      Collection of information concerning study endpoints will be performed by the investigator
      blinded to the results of preoperative testing of platelet function. The information will be
      collected from 60 patients undergoing cardiac surgery in the Department of Cardiac Surgery of
      Sheba Medical Center.

      Study endpoints

        1. Primary endpoint- resternotomy for bleeding after the surgery.

        2. Secondary endpoints- chest tube output during first 24 hours after the surgery;
           consumption of blood products during first 3 postoperative days.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2008</start_date>
  <completion_date type="Anticipated">December 2008</completion_date>
  <primary_completion_date type="Anticipated">October 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Re-sternotomy d/t Bleeding</measure>
    <time_frame>Hospitalization Period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Chest tube output during first 24 hours after the surgery</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Bleeding</condition>
  <arm_group>
    <arm_group_label>No Treatment</arm_group_label>
    <description>Patients with the history of ingestion of aspirin and/or ADP receptor antagonist (clopidogrel or ticlopidine) for at least 7 days prior the surgery. All patients undergoing cardiac surgery with the use of cardiopulmonary bypass on elective and urgent basis.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with the history of ingestion of aspirin and/or ADP receptor antagonist
        (clopidogrel or ticlopidine) for at least 7 days prior the surgery. All patients undergoing
        cardiac surgery with the use of cardiopulmonary bypass on elective and urgent basis.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing cardiac surgery with the history of aspirin and/or ADP receptor
             antagonist for at least 7 days prior the surgery

        Exclusion Criteria:

          -  Emergent surgery

          -  Heart transplant surgery

          -  Implantation of ventricular assist devices

          -  Enrollment into conflicting study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sergey Preisman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sheba Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexander Kogan, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sheba Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sergey Preisman, MD</last_name>
      <phone>052-6667205</phone>
      <email>sergey.preisman@sheba.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Sergey Preisman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2008</study_first_submitted>
  <study_first_submitted_qc>October 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2008</study_first_posted>
  <last_update_submitted>October 22, 2008</last_update_submitted>
  <last_update_submitted_qc>October 22, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 23, 2008</last_update_posted>
  <responsible_party>
    <name_title>Sergey Preisman, MD</name_title>
    <organization>Sheba Medical Center</organization>
  </responsible_party>
  <keyword>Thrombelastogram</keyword>
  <keyword>Microvascular bleeding</keyword>
  <keyword>antiplatelet medication</keyword>
  <keyword>cardiac surgery</keyword>
  <keyword>consumption of blood products</keyword>
  <keyword>preoperative platelet mapping derived from modified TEG</keyword>
  <keyword>postoperative bleeding</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

